No insider purchase over the last 90 days. The latest was filed 12 Nov 2025.
BillionToOne, Inc., founded in 2016, is a listed company based in United States. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 399 filings were filed, from 19 insiders.
On the market, 2 insiders bought (7 purchases totalling €2.3M) while 6 insiders sold (158 sales totalling €30.1M). The totals do not cover 35 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. At €2.0M, the sale published on 7 August 2026 by Atay Oguzhan is the largest of the period (0.043% of market cap). Those buying include 2 senior executives.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 12 November 2025, 340 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 399 filings, this issuer sits above that mark. Looking back to 2025, when coverage begins, insiders filed 7 purchases and 159 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 305.1 m USD and net income at 7.5 m USD.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
+2 other insiders
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate BillionToOne, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$129.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 400 declarations
BillionToOne, Inc. is a company focused on developing molecular diagnostic technologies. It specializes in innovative solutions for the early detection of genetic diseases.
Purchases our model currently ranks for the recommendations list.
All recommendationsInsider filings
Over the last 90 days, 146 filings published between 31 July and 16 October 2026: 72 sales for €20.0M. 74 other filings (not open-market purchases or sales: grants, options, plans, sale notices, block transfers). Largest amounts: Atay Oguzhan (Chairman and CEO), sales of €11.1M; Lynch Thomas P. (See Remarks), sales of €5.1M; Tsao David (Chief Technology Officer), sales of €3.6M.
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 18 October 2026 (UTC)
Headquarters: United States · Founded: 2016
Source: Wikidata (CC0).
| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2025 | 305.1 m USD | 7.5 m USD | 0.14 USD | 10-K |
| Dec 2024 | 152.6 m USD | -41.6 m USD | -4.12 USD | 10-K |
| Dec 2023 | 71.7 m USD | -82.7 m USD | -8.45 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.
BillionToOne's SVP sold again on October 5. Read the filing against Natera, sector valuation pressure, and what the clus...
BillionToOne’s September insider sales came as diagnostics stayed hot, peers traded unevenly, and the stock sat well bel...
BillionToOne’s CEO sold shares after a sharp Q2 print. We set the filing against Natera, Guardant and the biotech bid.